NanoViricides Inc. (NNVC)
NanoViricides Inc. (NNVC) Stock Price, Analysis & Data
| Bid | 1.36 |
| Market Cap | 35.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.09M |
| Beta | 1.69 |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.94 |
| P/B (ttm) | 3.26 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.36 |
| Volume | 218,158 |
| Avg. Volume (20D) | 907,890 |
| Open | 1.35 |
| Previous Close | 1.35 |
| Day's Range | 1.34 - 1.39 |
| 52-Week Range | 0.85 - 2.23 |
| Analyst | Strong Buy |
| Price Target | 6 (337.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections com...
Financial Performance
In 2025, NanoViricides's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -9.47M, an increase of 14.14%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for NNVC stock is "Strong Buy". The 12-month stock price forecast is 6, which is upside of 337.96% from the latest price.
Stock Forecasts
